PE: Can you elaborate on the key design elements of the AD04 study and how they contributed to achieving positive topline results? Claiborne: The purpose of the study was to evaluate the relative ...

CARLSBAD, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. (NAI) and CarnoSyn® Brands today announced the publication of positive clinical trial results in the ...

STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (Stockholm/Nasdaq: XSPRAY), a biotechnology company focused on developing improved protein kinase inhibitors (PKIs) for cancer treatment using its ...

AstraZeneca, in collaboration with Parexel International, is conducting a study titled An Open-Label, Randomized, Four-Treatment, Four-Period, Single-Dose Crossover Study in Healthy Participants to ...

RedHill Biopharma, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, together with IntelGenx Corp, a Canadian ...

Xspray Pharma provides an update on its second product candidate, XS003: New data shows matching bioavailability to Tasigna® at more than a 50% reduced dose. STOCKHOLM--(BUSINESS WIRE)-- Xspray Pharma ...

VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...

HELSINKI, Jan. 5, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial ...